Bladder cancer represents a global health problem. It ranks ninth in worldwide cancer incidence. Radical cystectomy with pelvic lymph node dissection is the treatment of choice for muscle invasive bladder cancer. In attempts to improve the results of radical cystectomy, adjuvant chemotherapy and radiotherapy in many trials are added to improve outcome .In the present study,in the radical cystecytectomy group (127 patients),72 patients(57%)didn't receive adjuvant therapy,55(43%) received adjuvant therapy Twenty four patients(19%) received adjuvant chemotherapy ,23 patients (18%)received adjuvant radiotherapy,8 patients (6%) received chemotherapy and radiotherapy as adjuvant treatment.The median DFS was 18.3 months for no adjuvant group and was not reached for adjuvant group and this was statistically significant (p=0.013)Our data demonstrate that addition of chemotherapy decreases risk of relapse by 68% and it was statistically significant (p=0.025). HR=0.318 (95%CI 0.110-0.918). In adjuvant radiotherapy group , 5 year DFS 61% compared to 5year DFS 22% in those who did not receive but this was not statistically significant (p=0.373).